Study Reveals EBV Variant and Host Gene Interaction as Key Driver of Nasopharyngeal Carcinoma Risk

A genetic interaction between the HLA-A*11:01 allele and the high-risk Epstein-Barr virus variant 85841G has been identified as a key determinant of nasopharyngeal carcinoma risk, according to research published in Nature. The study, conducted through a stepwise host-EBV genome interaction analysis, shows that this interaction drives substantially elevated risk far exceeding the effects of host or virus factors alone.

@Nature reported that individuals carrying a susceptible HLA-A background—defined as HLA-A11:01 negative or HLA-A02:07 positive—and infected with the high-risk 85841G EBV form a dual-risk subgroup.

5% of the population and accounts for approximately 47% of nasopharyngeal carcinoma cases. EBV infects more than 95% of adults worldwide but is associated with endemic nasopharyngeal carcinoma specifically in southern China. The research details how EBV 85841G encodes an EBNA3B peptide that binds to HLA-A*11:01 and elicits specific T cell responses capable of lysing EBV-positive B cells transformed by strains carrying 85841G.

The EBNA3B peptide is associated with reduced salivary viral load among A*11:01 carriers and lower nasopharyngeal carcinoma risk in that group. Evolutionary analysis conducted on EBV variant 85841G reveals it arose via ancient recombination events between northern and southern EBV strains. This variant subsequently underwent clonal expansion in southern China.

The clonal expansion led to co-enrichment of interacting host and viral risk factors, contributing to nasopharyngeal carcinoma endemicity. An article titled 'High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant' was published open access on 27 March 2026.

These findings reveal a stratified, interaction-driven risk architecture in the disease and highlight opportunities for precision prevention, as detailed in the Nature abstract.